Biogen’s Alzheimer drug Aduhelm proves drug prices are a lie

In mid-2021, American biotechnology company Biogen received the US Food and Drugs Administration (FDA)’s approval to market Aduhelm, its new drug to treat Alzheimer’s disease. The decision was controversial. FDA experts had advised against approving the drug, finding that its benefits were uncertain, and its most severe side effects—such as potentially deadly brain swelling—too frequent.

Read the source article at qz.com
2022-02-02 10:00:37